Abstract
BackgroundChronic infection with Burkholderia cepacia complex (BCC) has a detrimental effect on morbidity and mortality for patients with cystic fibrosis (CF). It is therefore logical to attempt to eradicate new isolates however there is a paucity of information to guide treatment. We report the successful eradication of new isolates of BCC in two children with CF.Case presentationBurkholderia cepacia was successfully eradicated in a 14 year old boy with CF and Burkholderia gladioli was successfully eradicated in a six year old girl with CF. In both children two weeks of intravenous (IV) tobramycin, ceftazidime and temocillin were used followed by three months of inhaled tobramycin. Bronchoalveolar lavage samples taken during flexible bronchoscopy were used prior to treatment to exclude spontaneous clearance as well as after treatment to confirm eradication.ConclusionsNew isolates of BCC can be successfully eradicated in children with CF. More research is urgently required in this area to identify the best treatment regimen for BCC eradication.
Highlights
Chronic infection with Burkholderia cepacia complex (BCC) has a detrimental effect on morbidity and mortality for patients with cystic fibrosis (CF)
New isolates of BCC can be successfully eradicated in children with CF
More research is urgently required in this area to identify the best treatment regimen for BCC eradication
Summary
New isolates of BCC can be eradicated in children with CF. This report identifies one possible eradication regimen using three IV antibiotics and one nebulised antibiotic. More research is required to establish which eradication regimen is the best for new isolates of BCC. Authors’ contributions FG and WL were the patients CF clinicians. They devised the article and edited the manuscript. HK wrote the first draft and subsequent versions. All authors have seen and approved the final version of the manuscript. Funding No funding was received for this article
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
